A Randomized, Double-blind, Phase III Trial to Compare the Efficacy and Safety of AK104 Combined With Chemotherapy to Tislelizumab Combined With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer (NSCLC)

AK104-307

This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK104 combined chemotherapy versus Tislelizumab combined chemotherapy in first-line treatment of Locally advanced or metastatic NSCLC with PD-L1 TPS \< 1%.

2023-11-14

2025-08-05

2026-11-28

Not yet recruiting

Early phase I

642

Inclusion Criteria: 1. The subjects voluntarily participated in the study with full informed consent and signed written informed consent form. 2. Aged ≥18 years when the subject signed the informed consent. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. Life expectancy ≥ 3 months. 5. Histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) that not amenable to complete surgical resection and not amenable to radical concurrent/sequential chemoradiation or metastatic (Stage IV) NSCLC (American Joint Committee on Cancer \[AJCC\] 8th edition). 6. No prior systemic therapy for advanced or metastatic NSCLC was received. 7. PD-L1 TPS \< 1%. 8. No EGFR sensitive mutations or ALK gene translocation alterations. Exclusion Criteria: 1. Histologically confirmed small cell lung cancer (SCLC). 2. NSCLC with driver gene mutations for approved targeted drug indications. 3. Active central nervous system (CNS) metastases were present. 4. Pulmonary radiation therapy \> 30 Gy within 6 months prior to first dose. 5. Active malignant tumors within the past 5 years, except for tumors in this study and scured local tumors. 6. Pregnant or lactating women. 7. Clinically significant cardiovascular or cerebrovascular disease. 8. Subjects with a known history of severe hypersensitivity to other monoclonal antibodies. A known history of allergy or hypersensitivity to all investigational drugs or any of their components. 9. Active autoimmune disease requiring systemic treatment within 2 years prior to the start of study treatment, or autoimmune diseases that may relapse or require scheduled treatment as judged by the Investigator. 10. Known active pulmonary tuberculosis. 11. Patients with active hepatitis B or active hepatitis C. 12. Known medical history of immunodeficiency or positive HIV test.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 642, 'type': 'ESTIMATED'}}

2023-08-14